Drug Trial Radar · NCT03656562
Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients
Last checked: Nov 19, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
107
Actual
Start
Dec 19, 2018
Primary completion
Jul 27, 2022
Study completion Apr 28, 2025
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 4, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to evaluate the safety, tolerability, pharmacokinetics and therapeutic efficacy of treatment with either VAY736 (ianalumab) or CFZ533 (iscalimab) in patients with systemic lupus erythematosus (SLE) to enable further development of these compounds as treatment in this disease population
Conditions
- Systemic Lupus Erythematosus (SLE)
Interventions
VAY736Drug
150 mg powder in vial for solution for injection; after reconstitution to 150 mg/mL per vial, a dose of 300 mg
VAY736 PlaceboDrug
solution for injection; 0 mg/mL administered as 2 mL s.c. injection
CFZ533Drug
150 mg/mL as concentrate in vial for infusion, administered at a dose of 10 mg/kg as i.v. infusion
CFZ533 PlaceboDrug
Placebo as concentrate in vial for infusion, administered at a dose of 10 mg/kg as i.v. infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With SLE Responder Index (SRI)-4 Response Status at Week 29 With Reduced Steroid Dose Maintained Between Weeks 17 and 29Time frame: Baseline, Week 17 to Week 29
Locations
31 sites in 15 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Caba, Argentina
Novartis Investigative Site
Clayton, Victoria, Australia
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Guangzhou, Guangdong, China
Novartis Investigative Site
Nanjing, Jiangsu, China
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Pessac, France
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Debrecen, Hajdu Bihar Megye, Hungary
Novartis Investigative Site
Ramat Gan, Israel
Novartis Investigative Site
Nagoya, Aichi-ken, Japan
Novartis Investigative Site
Nagoya, Aichi-ken, Japan
Novartis Investigative Site
Chuo Ku, Tokyo, Japan
Novartis Investigative Site
Shinjuku Ku, Tokyo, Japan
Novartis Investigative Site
Shinjuku-ku, Tokyo, Japan
Novartis Investigative Site
Bydgoszcz, Poland
Novartis Investigative Site
Poznan, Poland
Novartis Investigative Site
Warsaw, Poland
Novartis Investigative Site
Moscow, Russia
Novartis Investigative Site
Saint Petersburg, Russia
Novartis Investigative Site
Yekaterinburg, Russia
Novartis Investigative Site
Gwangju, South Korea
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Taichung, Taiwan
Novartis Investigative Site
Taichung, Taiwan
Novartis Investigative Site
Taichung, Taiwan ROC, Taiwan
Novartis Investigative Site
Bangkok, Thailand
Novartis Investigative Site
Bangkok, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.